Compare AbbVie Inc (ABBV) vs ArcelorMittal SA (MT) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

ArcelorMittal (MT) trades at $63.15, down 0.39% on the day, with a bullish technical signal supported by moving averages. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, and maintains a reasonable valuation with a P/E of 17.11 and P/S of 0.81. Recent news highlights expansion initiatives, a share buyback program, and a strategic AI collaboration with AWS to drive efficiency and lower-carbon steel production.

The outlook for MT is positive, driven by operational expansions and favorable steel import policies in Europe and the US, though risks include high capital expenditures and exposure to Chinese market weakness. Analyst sentiment is predominantly bullish with 50% buy ratings, supporting potential upside if earnings growth continues.